Aytu BioPharma Plans To Divest / Discontinue Non Core Assets
Aytu BioPharma Inc (NASDAQ:AYTU) will divest or discontinue non-core, unprofitable products, including Cefaclor, Flexichamber, Tuzistra XR, generic Tussionex, and Zolpimist. Aytu expects to improve gross margins for its ADHD product franchise by transferring manufacturing to a well-established, global commercial manufacturing organization, a transition expected to occur in mid-2023. Aytu is commercializing two novel…
Benzinga ·
Benzinga
